Biosimilarity: The FDA Perspective
商品資訊
商品簡介
Summary:
The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.
Features:
First comprehensive analysis based on new guidelines and approval packages of several biosimilars
Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.
Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines
Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies
Allow creation of a fast-to-market pathway to develop biosimilars
您曾經瀏覽過的商品
購物須知
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。